Supplementary Data 2 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration

Supplementary Data 2 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration

<p>DEG Table for R vs NR (mRNAseq)</p>

保存先:

書誌詳細
第一著者:	Gregory L. Beatty (15087193) (author)
その他の著者:	Devora Delman (15129986) (author), Jiayi Yu (16743347) (author), Mingen Liu (16743350) (author), Joey H. Li (15129989) (author), Liti Zhang (16743353) (author), Jae W. Lee (16743356) (author), Renee B. Chang (15129983) (author), Nathan Bahary (16743359) (author), Eugene P. Kennedy (16743362) (author), Andrea Wang-Gillam (15049923) (author), Gabriela R. Rossi (16743365) (author), Ignacio Garrido-Laguna (15131889) (author)
出版事項:	2025
主題:	Cancer Therapeutic Research and Development Chemotherapy Gastrointestinal Cancers Pancreatic cancer Translational Research
タグ:	タグ追加タグなし, このレコードへの初めてのタグを付けませんか!

類似資料

Supplementary Data 1 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
著者:: Gregory L. Beatty (15087193)
出版事項: (2025)

Supplementary Data from <i>N</i><sup>6</sup>-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer
著者:: Jiachun Su (16990970)
出版事項: (2025)

Image 9_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
著者:: Xiangjun Wang (2522917)
出版事項: (2025)

Image 8_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
著者:: Xiangjun Wang (2522917)
出版事項: (2025)

Image 6_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
著者:: Xiangjun Wang (2522917)
出版事項: (2025)

Image 7_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
著者:: Xiangjun Wang (2522917)
出版事項: (2025)

Image 4_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
著者:: Xiangjun Wang (2522917)
出版事項: (2025)

Image 5_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
著者:: Xiangjun Wang (2522917)
出版事項: (2025)

Image 3_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
著者:: Xiangjun Wang (2522917)
出版事項: (2025)

Image 1_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
著者:: Xiangjun Wang (2522917)
出版事項: (2025)

Image 2_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
著者:: Xiangjun Wang (2522917)
出版事項: (2025)

Table 3_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.docx
著者:: Xiangjun Wang (2522917)
出版事項: (2025)

Table 2_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.docx
著者:: Xiangjun Wang (2522917)
出版事項: (2025)

Table 1_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.docx
著者:: Xiangjun Wang (2522917)
出版事項: (2025)

Supplementary Table S1 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
著者:: Erika Y. Faraoni (14844897)
出版事項: (2025)

Supplementary Table S3 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
著者:: Erika Y. Faraoni (14844897)
出版事項: (2025)

Supplementary Table S4 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
著者:: Erika Y. Faraoni (14844897)
出版事項: (2025)

Supplementary Figure S1 from First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001
著者:: Yan Zhou (15053225)
出版事項: (2025)

Supplementary Movie S1 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
著者:: Fang Wei (15057172)
出版事項: (2025)

Supplementary Movie S2 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
著者:: Fang Wei (15057172)
出版事項: (2025)

Supplementary Movie S3 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
著者:: Fang Wei (15057172)
出版事項: (2025)

Supplementary Movie S4 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
著者:: Fang Wei (15057172)
出版事項: (2025)

Supplementary Movie S5 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
著者:: Fang Wei (15057172)
出版事項: (2025)

Supplementary Movie S6 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
著者:: Fang Wei (15057172)
出版事項: (2025)

Supplementary Movie S7 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
著者:: Fang Wei (15057172)
出版事項: (2025)

Supplementary Movie S8 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
著者:: Fang Wei (15057172)
出版事項: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
著者:: Arun Kanakkanthara (14937731)
出版事項: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
著者:: Arun Kanakkanthara (14937731)
出版事項: (2025)

Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
著者:: Elizabeth R. Tucker (15053624)
出版事項: (2025)

Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
著者:: Elizabeth R. Tucker (15053624)
出版事項: (2025)

Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
著者:: Elizabeth R. Tucker (15053624)
出版事項: (2025)

Figure S4 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
著者:: Elizabeth R. Tucker (15053624)
出版事項: (2025)

Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
著者:: Elizabeth R. Tucker (15053624)
出版事項: (2025)

Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
著者:: Elizabeth R. Tucker (15053624)
出版事項: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
著者:: Dwight H. Owen (15034782)
出版事項: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
著者:: Dwight H. Owen (15034782)
出版事項: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
著者:: Dwight H. Owen (15034782)
出版事項: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
著者:: Dwight H. Owen (15034782)
出版事項: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
著者:: Dwight H. Owen (15034782)
出版事項: (2025)

Supplementary Table 1 from Comprehensive DNA Methylation Analysis Indicates That Pancreatic Intraepithelial Neoplasia Lesions Are Acinar-Derived and Epigenetically Primed for Carcinogenesis
著者:: Emily K.W. Lo (15618846)
出版事項: (2025)

Cannot write session to /tmp/vufind_sessions/sess_q3q7mq78ftdfib2sedc66ns249